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ABSTRACT 
SPAK and OSR1 are two cytoplasmic serine/threonine protein kinases that regulate the 
function of a series of sodium, potassium and chloride co-transporters via phosphorylation. 
Over recent years, it has emerged that these two kinases may have diverse function beyond the 
regulation of ion co-transporters. Inspired by this, we explored whether SPAK and OSR1 
kinases impact physically and phosphorylate the b2-adrenergic receptor (b2ADR). Herein, we 
report that the amino acid sequence of the human b2ADR displays a SPAK/OSR1 consensus 
binding motif and using a series of pulldown and in vitro kinase assays we show that SPAK 
and OSR1 bind the b2ADR and phosphorylate it in vitro. This work provides a notable example 
of SPAK and OSR1 kinases binding to a G-protein coupled receptor and taps into the potential 
of these protein kinases in regulating membrane receptors beyond ion co-transporters.  
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1. INTRODUCTION 
The with-no-lysine (WNK) serine/threonine protein kinases 1-4 are key regulators of ion 
homeostasis [1-3]. Mutations in the genes that encode these kinases cause an inherited form of 
hypertension known as Gordon’s syndrome (Fig. 1a) [4]. The genetic link between WNK-
signalling and hypertension was further strengthened in 2012 when it was reported[5, 6] that 
mutations in two ubiquitin E3 ligases known as kelch-like 3 (KLHL3) and Cullin 3 (Cul3), 
which we[7] and others[8, 9] later found to control the activity of WNK kinases, resulted in 
hypertension (Fig. 1a).  
WNK kinases bind to and phosphorylate two serine/threonine protein kinases termed Ste20p-
related proline alanine-rich kinase (SPAK) and oxidant stress-responsive protein kinase 1 
(OSR1), [10] which in complex[11] with the scaffolding mouse only protein 25 (MO25) 
phosphorylate a plethora of sodium, potassium and chloride ion co-transporters such as the 
Na+-K+-Cl- co-transporters 1 and 2 (NKCC1 and NKCC2, respectively) and the Na+-Cl- co-
transporter (NCC) (Fig. 1a) [10].  
To date, most studies on the WNK-SPAK/OSR1 signalling cascade have focused on its role in 
regulating blood pressure through the phosphorylation of ion co-transporters [1, 2]. In 2011, 
however, the transcription of the WNK4 gene in the kidney was reported to be regulated by the 
b2ADR[12] though some of these findings were later contested [13]. In 2013, a study from the 
Kobilka lab where the b2ADR was pulled down from bovine heart lysates treated with either 
the inverse agonist carazolol or the full agonist BI-167107 followed by proteomics identified 
ca. 250 endogenous proteins as possible binders to the b2ADR among which was the protein 
kinase SPAK [14]. Collectively, these studies provided an indication of a possible novel and 
unexplored crosstalk between the WNK-signalling pathway and the β2ADR. Intrigued by these 
studies, we embarked on verifying whether SPAK and OSR1 kinases bind and phosphorylate 
the β2ADR.  
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2. MATERIALS AND METHODS 
2.1. Materials. The synthetic biotinylated 18-mer RFQV containing peptide (biotin-C6-
SEEGKPQLVGRFQVTSSK, catalogue number; 331938), AFQV containing peptide (biotin-
C6-SEEGKPQLVGAFQVTSSK, catalogue number: 372447), RFHV containing peptide 
(biotin-C6-DKSEGRFHVQNLSQ, catalogue number: 372432), and AFHV containing peptide 
(biotin-C6-DKSEGAFHVQNLSQ, catalogue number: 372438) as well as CATCHtide 
(RRHYYYDTHTNTYYLR-TFGHNTRR) were purchased from GLS Peptide synthesis, 
Shanghai, China. The cDNA plasmids pCMV5-GST-EV (DU41864), pEBG-HA- SPAK 
(DU2923), pCMV5-FLAG-NKCC2-FL-WT (DU10098), pcDNA5-FRT/TO- FLAG-NKCC2-
R20A (DU17023), pCMV-FLAG-NKCC2 (1-174) WT (DU13857), pCMV5-FLAG-β2AR-
R239A (DU39345), pEBG-HA-OSR1T185E (DU6130), pGEX- NKCC2 (1-174) (DU13763), 
pGEX-OSR1-T185E full length (DU 6231) and pGEX- MO25α (DU2945) were purchased 
from the MRC PPU Reagents and Services (Dundee). pcDNA5-FRT/TO-FLAG-β2AR-WT 
(lot:390869S) was purchased from GenScript. 
2.2.  Buffers. Lysis buffer 1 (LB1). Cell lysis buffer: 50 mM Tris/HCl (pH 7.5), 1 mM sodium 
orthovanadate, 1 mM EGTA, 1 mM EDTA, 50 mM sodium fluoride, 0.27 M sucrose, 5 mM 
sodium pyrophosphate, 1 % (w/v) Nonidet P40 plus protease inhibitors 0.1 mM 
phenylmethanesulfonylfluoride (PMSF), 1 mM benzamidine, and 0.1 % (v/v) 2- 
mercaptoethanol. Lysis buffer 2 (LB2) was LB1 supplemented with 1 % (w/v) n-dodecyl β-D-
maltoside (catalogue number; 89902, ThermoFisher). Lysis buffer 3 (LB3) was used to 
solubilize β2AR-transfected mammalian cells and it contained 50 mM HEPES (pH 7.5), 0.5 % 
Nonidet P40, 145 mM sodium chloride, 2 mM EDTA, and 10 % (v/v) glycerol, 0.1 mM PMSF, 
1 mM benzamidine, 0.1 % (v/v) 2-mercaptoethanol and 1 % (w/v) final concentration of n- 
dodecyl β-D-maltoside was freshly added before cell lysing. Buffer A:[11] 50 mM Tris–HCl 
(pH 7.5), 0.1 mM EGTA and 0.1% (v/v) 2-mercaptoethanol. 
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2.3. Cell culture.  Mammalian cells were cultured in T-75 flasks, 10-cm or 6-well plates. The 
cells were cultured in DMEM supplemented with 10 % (v/v) FBS and 1 % (v/v) Pen/Strep. 
Once they reached 80-90 % confluency (log phase), the cells were regularly passaged in 1:5 
ratio every 2-3 days. The cells were washed once by 3-5 ml of PBS after the removal of the 
media. Then, they were detached with 2 ml trypsin. Typically, the cells were grown in 12-15 
ml media in T75, 7 ml media in 10-cm dishes or 3 ml media in the 6-well plates. All of the 
flasks and plates were maintained at 5 % CO2 humified incubator at 37 °C.  
For protein expression in mammalian cells, HEK293 cells (passage range 5-25) were plated 
either in 6-well plates or 10-cm dishes. Once the cells reached 40-50 % confluency, they were 
transfected using the PEI method as reported previously[10]. 1 μg of cDNA clones with 2 μl 
of 1 mg/ml PEI was mixed in a ratio of 1:2 in 200 μl FBS-free DMEM media per well of 6-
well plates. 3 μg cDNA with 20 μl 1 mg/ml PEI in 1 ml FBS- free DMEM media for a single 
10-cm dish. Then, the mixture was vortexed gently and left at room temperature for 25 min. 
This mixture was then added to the cells carefully to avoid their detachment and the cells were 
incubated at 37 °C. 36-48 hrs post-transfection, the cells were harvested, or underwent 
treatment as needed. 
2.4. Preparation of mouse heart samples. The mouse heart samples were prepared as 
previously reported [15].  
2.5. Pulldown and Immunoprecipitation Protocols. 
2.5.1. Biotin-RFxV pulldown of SPAK and OSR1  
Once HEK293 cells cultured in 10-cm dishes were 80-90 % confluent, they were harvested 
and lysed. Then 1-5 mg of the total cell lysates was incubated with 3 μg of either the RFQV-
peptide, the RFHV-peptide, the AFQV-peptide or the AFHV- peptide for 15 min at 4 °C on 
rotator shaker. After incubation, 40 μl of streptavidin 50 % slurry (which had been washed and 
equilibrated in lysis buffer) was added to each sample. The samples were then incubated on 
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rotator shaker for 15 min at 4 °C.[16] After that, the beads were collected by centrifuging at 
1,000 g for 2 min at 4 °C. The beads were subsequently washed twice with 1 ml LB1 and 
washed again twice with 1 ml buffer A. Finally, the beads were prepared for SDS-PAGE as 
described below.  
2.5.2. GST affinity pull down 
Once cultured HEK293 cells in 10-cm dishes reached 50 % confluency, they were transfected 
with glutathione S-transferase (GST)-tagged proteins e.g. SPAK and OSR1 alone, or co-
transfected with other FLAG-fusion proteins. 36 hrs post-transfections, the cells were 
harvested by adding 0.4 ml of suitable lysis buffer. Then, the cell suspensions were collected 
and clarified from cellular debris by centrifugation at 12,000 g for 10 min at 4 °C. The 
supernatants were collected, and protein concentration was measured by the Bradford assay 
and the samples were prepared for SDS-PAGE to assess protein expression while the remaining 
lysates were stored at -80 °C.  
Pulldown of GST-tagged proteins was carried out by using glutathione Sepharose high 
performance (GST) beads (catalogue number: 17-527-01, GE Healthcare). GST beads were 
washed with 1 ml PBS three times by incubating with PBS and then centrifuging at 1,000 g at 
4 °C for 5 min. After this, the collected GST- beads equilibrated in PBS at 50 % slurry. 0.5 mg 
of the cell lysates was incubated on rotator shaker in a 20 μl slurry of GST-beads either 
overnight at 4 °C or 1 hr at room temperature.[16] The beads were then collected by 
centrifugation at 1,000 g at 4 °C for 5 min. The collected beads were washed twice with 1 ml 
LB1 and twice with 1 ml buffer A. Finally, the beads were prepared for SDS-PAGE 
electrophoresis as described below. 
2.5.3. Affinity pulldown of FLAG-β2AR  
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HEK293 cells were cultured and transiently transfected in 10-cm plates using PEI. 36-48 hrs 
post-transfection, the cells were washed once with 2 ml ice-cold PBS and detached by adding 
400 μl/plate of ice cold LB3. Following cell detachment by scrappers, the suspension was 
vortexed and incubated on rotator shaker for 2 hrs or overnight at 4 °C.[15] The lysate was 
subsequently centrifuged at 12,000 g for 10 min at 4 °C. The supernatant was collected, and 
samples were prepared for SDS-PAGE to check receptor expression while the remaining lysate 
was stored at -80 °C.  
In order to isolate FLAG-β2AR from cell lysate, pre-clearing of the cell lysate was first 
performed three times by incubating 1 mg cell lysate with 100 μl of 50 % slurry of protein-G-
Sepharose beads (GE Health care life sciences, catalogue number: PG5- 161501) on rotator 
shaker at 4 °C for 10 min. After this, the beads were collected by centrifuging at 1,000 g at 4 
°C for 5 min. Anti-FLAG antibody (F3165, Sigma) conjugated to the protein-G Sepharose 
beads was added to the pre-cleared lysate at a ratio of 1:100, (10 μg conjugated-antibody: 1 mg 
cell lysate).[10] After incubation for 1 hr on rotator shaker at 4 °C, the solid beads were 
collected by centrifuging at 1,000 g for 5 min at 4 °C. The beads were then washed twice by 
resuspending in 1 ml of LB3, centrifuging at 1,000 g for 5 min at 4 °C. For preparing samples 
for kinase assay, beads were washed two more washes with LB3 contained 0.5 M NaCl. After 
the last spin the beads were subsequently washed twice by resuspending in 1 ml buffer A and 
centrifuging at 1,000 g for 5 min at 4 °C. For Western blotting, proteins were eluted from the 
beads, by adding 60-80 μl of 1x SDS-sample buffer, mixed well by a bench vertex and heated 
in a dry heater at 90 °C for 10 min. Then samples were stored at -20 °C.  
2.5.4. Immunoprecipitation of endogenous OSR1/SPAK  
To immunoprecipitate endogenous SPAK from the mouse heart, pre-clearing steps were 
carried out as before. Then, 50 μg of conjugated anti- OSR1 or anti-SPAK antibody was added 
to 5 mg of total protein lysate [10]. After incubation for 1 hr on rotator shaker at 4 °C, the beads 
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were collected by centrifuging at 1,000 g for 5 min at 4 °C. The beads were washed twice by 
resuspending in 1 ml LB1, then centrifuging at 1,000 g for 5 min at 4 °C. After the last spin, 
the beads were washed twice by resuspending in 1 ml buffer A and centrifuging at 1,000 g for 
5 min at 4 °C. Then, 60 μl of 1x SDS-sample buffer was added to the beads and mixed well by 
bench vertex. Subsequently, the samples were either prepared for SDS-PAGE as before or 
stored at -20 °C. 
2.6. SDS-PAGE electrophoresis and Western blotting.  These were conducted using the 
protocols that were reported by Filippi B.M. et al. 2011[11].  
2.7. ADP-GloTM In Vitro Kinase Assay. OSR1-T185E, MO25α and NKCC2 (1-174) were 
expressed and purified from LB21 E.coli as reported previously[11] while FLAG-β2AR was 
immunoprecipitated from transfected HEK293 cells. Non-radioactive ATP was used in this 
assay. The kinase reaction was performed in 1.5 ml Eppendorf tubes at a final volume of 25 
μl/reaction in triplicate. Each reaction contained 0.4 μM OSR1-T185E with the presence or 
absence of 2 μM MO25α. The substrates were either 250 μM CATCHtide 
(RRHYYYDTHTNTYYLRTFGHNTRR), 5 μM GST-cleaved NKCC2 (1-174) that were used 
as positive control, or 10 μg beads conjugated to immunoprecipitated β2AR. After all proteins 
were freshly prepared in kinase buffer which containing 10 mM MgCl2, and 0.1 mM ATP.[17] 
The samples were incubated on 30 °C for 40 min on gentle agitation. Then, the samples were 
transferred into a 96-wells plate and developed according manufacturer’s instructions (ADP-
GloTM kit, Promega). This involved adding 25 μl of reagent-1 to each sample and incubation 
for 40 min at room temperature. Then, 50 μl of reagent-2 was added to each sample followed 
by incubation for 1 hr at room temperature.[18] The luminesce was subsequently measured by 
reading the plate on BMG FLUOStar Omega plate reader. The results were analysed by Graph 
Pad Prism and the data was presented as mean ± SD of three independent experiments.  
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3. RESULTS AND DISCUSSION 
The binding of SPAK and OSR1 kinases to their upstream kinases, WNKs, and downstream 
ion co-transporters is mediated by their highly conserved C-terminal domains, which bind 
unique Arginine-Phenylalanine-any amino acid-Valine/Isoleucine (RFx[V/I]) tetrapeptides 
from the upstream and downstream protein binders [19]. With this in mind, we first analysed 
the amino acid sequence of the human βADRs 1-3 to determine if they have the SPAK/OSR1 
binding motif. Such analysis showed that the human β2ADR possesses an RFHV motif (239-
242), which matches perfectly the SPAK/OSR1 RFx[V/I] consensus binding motif, while  
human β1 and β3ADRs did not (Fig. 1b). Previous work focused on determining the 3D 
structure of the human β2ADR indicated that the RFHV motif is located in the cytoplasmic 
loop (loop 3) of the β2ADR [20], thus supporting its possible binding to cytoplasmic proteins.  
To establish whether the β2ADR’s RFHV motif mediates binding to SPAK and OSR1 kinases, 
we synthesised an N-terminally biotinylated 14-mer peptide derived from the human β2ADR 
(aa. 234-248), which contains the RFHV motif. In addition, we also synthesised the same 
peptide with one single point mutation where the arginine (R) of the RFHV motif was mutated 
to alanine to generate the corresponding ARHV 14-mer peptide. As controls, we used an 18-
mer RFQV peptide derived from WNK4 and its single point mutant 18-mer AFQV peptide 
[16]. These peptides were then incubated individually with HEK293 lysates, which 
endogenously express SPAK and OSR1 kinases. This was then followed by a biotin-
streptavidin pulldown assay and the results showed that the positive control RFQV peptide 
pulled down endogenous SPAK while its corresponding AFQV did not as expected (Fig. 2a) 
[16]. Encouragingly, the β2ADR-derived RFHV peptide pulled down endogenous SPAK while 
its corresponding AFHV mutant did not (Fig. 2a). This suggested that this β2ADR-derived 
motif mediated the binding to SPAK. Next, we overexpressed full-length GST-tagged SPAK 
wild-type (WT) and FLAG-tagged β2ADR in HEK293 cells. GST-affinity pulldown of the 
 10 
overexpressed SPAK resulted in a clear pulldown of the overexpressed FLAG-tagged β2ADR 
as shown by the FLAG blot (Fig. 2b). Interestingly, the addition of the synthetic SPAK-derived 
18-mer RFQV peptide to the cell lysates resulted in competing out FLAG- β2ADR binding to 
GST-SPAK (Fig. 2b). GST-pulldown from untransfected cells and the GST empty vector cells 
did not show any detectable FLAG- β2ADR binding (Fig. 2b). To investigate this further, in 
HEK293 we overexpressed a fragment of FLAG-tagged NKCC2 WT, a physiological substrate 
of SPAK and OSR1 kinases, and its R20A mutant, which is known not to bind SPAK and 
OSR1 [16]. In parallel, we also overexpressed full-length FLAG-tagged β2ADR WT and its 
R239A mutant, which corresponds to the AFHV mutant peptide. Following GST-pulldown, 
we performed Western blotting for FLAG. As expected, NKCC2 WT was pulled down while 
the binding to its R20A mutant led to significant reduction of binding to GST-SPAK (Fig. 2c). 
Encouragingly, GST-SPAK pulldown resulted in pulling down FLAG- β2ADR WT, but not its 
R239A mutant (Fig. 2c). The GST and FLAG blots of the total lysate confirmed the 
overexpression of SPAK, NKCC2 and β2ADR WT and mutants in equal amounts (Fig. 2c). 
To establish if the ß2ADR binds SPAK and OSR1 when expressed at endogenous levels in 
native tissue, endogenous SPAK was immunoprecipitated from mouse heart lysates. To 
maximise the extraction of the β2ADR from the membrane, we used two different mild 
detergents in lysing the mouse heart tissues; NP40 and NP40 plus dodecyl β-D-maltoside 
(DβM), a combination that was used previously with success in immunoprecipitating 
β2ADR[15]. The results showed that the immunoprecipitation of endogenous SPAK pulled-
down endogenous β2ADR (Fig. 2d) and this was more prominent in the DβM-containing lysis 
buffer. Critically, the empty beads did not show any pull down of β2ADR (Fig. 2d). This 
provided a compelling evidence of the binding of SPAK and the β2ADR at the endogenous 
level.  
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Once the binding of SPAK to the β2ADR was confirmed, we then explored whether SPAK and 
OSR1 kinases phosphorylate the β2ADR in vitro. First, OSR1 T185E, where the threonine was 
swapped into a glutamic acid to mimic phosphorylation and generate a constitutively active 
OSR1,[10] was used to phosphorylate FLAG-β2ADR WT and GST-NKCC2 (1-174) (as a 
positive control). The results showed that OSR1 T185E was able to phosphorylate GST-
NKCC2 in vitro as expected and this was suppressed by verteporfin, an OSR1 inhibitor[17] 
(Fig. 3a). Interestingly, OSR1 T185E was also able to phosphorylate FLAG-β2ADR WT to the 
same extent as the known substrate NKCC2 (Fig. 3a). Notably, the in vitro phosphorylation of 
the FLAG-β2ADR WT by OSR1 T185E was also supressed by the OSR1 inhibitor verteporfin 
(Fig. 3A). Using the same kinase assay and employing the FLAG-β2ADR R239A protein as a 
substrate led to a significant reduction in its phosphorylation by OSR1 T185E as compared to 
that observed with FLAG-β2ADR WT (Fig. 3b).  
In conclusion, this work provides evidence of SPAK and OSR1 kinases binding to the β2ADR 
and that these kinases phosphorylate in vitro this pharmacologically important G-protein 
coupled receptor. The results presented herein will stimulate further research into mapping the 
exact phosphorylation sites of the β2ADR that are phosphorylated by SPAK and OSR1 kinases 
as well as efforts aimed at unravelling the physiological relevance of such phosphorylation. 
Additionally, they suggest that SPAK and OSR1 kinases are likely to bind and regulate the 
function of other membrane receptors beyond ion co-transporters, a possibility that is currently 
unexplored.  
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FIGURES  
 
Figure 1. a. A representation of the main components of the WNK-SPAK/OSR1 signalling 
pathway. WNK kinases phosphorylate SPAK and OSR1, which in complex with the 
scaffolding protein MO25, phosphorylate a series ion co-transporters such as NKCC1/2, NCC 
and KCC. (-) indicates inhibition while (+) indicates activation. b. Sequence alignment of the 
human βADR 1-3 showing the region of the β2ADR with the possible SPAK/OSR1 RFHV 
binding motif (shaded in green). The yellow shaded regions are transmembrane sequences. The 
sequence alignment was conducted using UniProt Align. 
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Figure 2. SPAK and OSR1 kinases bind the β2ADR. a. 5 mg of untransfected HEK293 lysate 
was incubated with 3 μg of 1) the 18-mer RFQV peptide (SEEGKPQLVGRFQVTSSK 
equivalent to human SPAK amino acids 379-394), which bind SPAK and OSR1, 2) its single 
point mutant 18-mer AFQV peptide (SEEGKPQLVGAFQVTSSK equivalent to human SPAK 
amino acids 379-394), which does not bind SPAK and OSR1, 3) 14-mer RFHV peptide 
(DKSEGRFHVQNLSQ) derived from the human β2ADR (amino acids aa. 239-242) and 4) its 
corresponding mutant single point mutant 14-mer AFHV peptide (DKSEGAFHVQNLSQ). 
All of these peptides carry an N-terminal biotin. Following streptavidin-biotin, pull down the 
material underwent western blotting for endogenous SPAK. n = 3. b. HEK293 were co-
transfected with GST-SPAK full length and FLAG-β2ADR. The cells were lysed 48 h post-
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transfection and the lysates were incubated with the 18-mer RFQV peptide for 2 h at 4 °C 
where indicated. Following GST-pull down, the pulled down material was blotted for FLAG 
to check FLAG-β2ADR pull down. c. HEK293 cells were transiently transfected with GST 
empty vector or co-transfected with GST-SPAK wildtype and either with Flag-NKCC2 full-
length wildtype or its mutant R20A, or FLAG- β2ADR wildtype or FLAG-β2ADR R239A. 
After GST pulldown, the samples underwent western blotting for FLAG. d. Mouse heart tissues 
were lysed in either a lysis buffer containing the detergent NP40 or a lysis buffer with NP40 
supplemented with DbM. Endogenous SPAK was subsequently immunoprecipitated from both 
samples and the obtained material underwent Western blotting for SPAK.  
 
 
Figure 3. OSR1 phosphorylates β2ADR in vitro. a. OSR1 T185E, where T185 was mutated 
into glutamic acid to mimic phosphorylation and generate a constitutively active OSR1,[11] 
was used to phosphorylate FLAG-β2ADR WT and GST-NKCC2 (1-174) in the presence or 
absence of the OSR1 inhibitor Verteporfin. b. Phosphorylation of FLAG-β2ADR WT and its 
R239A mutant by OSR1 T185E in vitro. Phosphorylation of the OSR1 peptide substrate 
CATCHtide[16] was used as a control. FLAG and GST blots were used to show the loading of 
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the β2ADR WT, its R239 mutant and the NKCC2 (1-174). The FLAG-β2ADR WT and R239A 
were pulled down from 200 µg of HEK293 total lysates overexpressing the FLAG-tagged 
protein using 10 µg of FLAG antibody conjugated to sepharose beads. GST-NKCC2 (1-174) 
was purified from E.coli as reported,[21] and the in vitro kinase assay was conducted using 
Promega’s ADP-Glo as we reported previously.[18] All results are represented as mean ± 
S.E.M for triplicate samples, P value was calculated by one-way ANOVA, P < 0.05 was 
determined as statistical significance. (***): P value = 0.0001 and (**): P value =0.0025. 
 
 
 
